Blog | HemaCare

In an independent study recently published by Pfizer, ^[1] natural killer (NK) immune cells sourced from HemaCare were evaluated to test how well suited they are for use in cytotoxic activity assays.

These last few years have seen the successful clinical development of several monoclonal antibody-based treatments for cancer and inflammatory disease. These antibodies are designed to act in a number of different ways, from tagging target cells so they can be recognized by the immune system, to blocking growth or metastasis, to attacking problematic cells themselves. Monoclonal antibodies (m’Abs) are seen as particularly beneficial because they can be used to complement more traditional therapies and because their use generally results in fewer side effects.

Scientists created a tiny heart in the lab using stem cells

Stem cell research is continuously evolving and will likely become more and more effective in the near future. Researchers are continuously making efforts to grow stem cell-based organs in the lab using 3D modeling. Developing patient-specific organs to replenish degenerated organs or to screen drugs is a Holy Grail for the revolutionary tissue engineering field.

Researchers use novel technology that skips the RNA isolation step. Whole blood provided by HemaCare was important in demonstrating the approach.

A recent paper demonstrates how peripheral blood mononuclear cells (PBMCs) can be used to detect CFTR protein in an easy and non-invasive way by flow cytometry.